07:54 AM EDT, 09/11/2025 (MT Newswires) -- Silexion Therapeutics ( SLXN ) said Thursday that preclinical data showed that its drug candidate SIL204 reaches all primary sites of pancreatic cancer metastasis with anti-tumor activity.

The data showed drug distribution to the liver, peritoneum and lung with "statistically significant" tumor reduction across multiple sites after SIL204 was subcutaneously administered to a metastatic pancreatic cancer mouse model, the company said.

Silexion said it expects to initiate phase 2/3 clinical trials evaluating its dual-route administration approach in H1 of 2026, with regulatory submissions planned for Q4 of this year and Q1 of 2026.

Shares jumped more than 160% in recent premarket activity Thursday.